fashion -WSS

fashion

author：focus 2025-09-05 15:43:34 - browse：78

Illustration of a prescription bottle image on the screen of a smart phone – medical tech coverage from STAT — Alex Hogan/STAT

In another sign of the business headwinds facing prescription mental health apps, developer Twill will shop around for a pharmaceutical company to market Aspiro, its cognitive behavioral therapy treatment for both generalized anxiety and major depression.

Twill executives told STAT the company hopes that a drugmaker developing or currently marketing a product for generalized anxiety, or GAD, and major depressive disorder, or MDD, will be interested in adding a digital therapeutic to boost the effect of its drug — as well as its sales. Twill’s chief strategy officer Chris Wasden said that after watching companies built around prescription digital therapeutics, or PDTs, stall out, Twill made the decision earlier this year that it would only take the product to market if it found a willing drugmaker to serve as its partner.

“A PDT is going to be more valuable in the hands of a drug company that has a drug that they would like to get greater adherence [and] greater revenues from rather than trying to get reimbursement for the PDT itself,” he said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Be careful with at

leisure time

WSS

Hospitals are dialing back on venture capital investing

In Spain, a hospital brews its own CAR

YouTube cracks down on misinformation on cancer treatment

Illumina slashes 2023 revenue projections yet again

After Optum profits sink, UnitedHealth makes changes

Can sheer will power keep patients alive in their dying hours?

hotspot

fashion

hotspot

The high cost of giving birth even with insurance

Violet CEO on training clinicians to promote more inclusive care

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Prime Medicine, Myeloid Therapeutics clash over genome

Bright Health sells Medicare Advantage business to Molina

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Psychedelics group wrestles with new pharma identity

Indictment alleges Trump's ex

How one medical school became remarkably diverse

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

leisure time

Aspartame and sugar

Dozens dead from Maui wildfires: What we know about the victims

Treatments for cramps don't cut it. Why aren't there better options?

What to know about the judge who will handle the Trump case

Dozens dead from Maui wildfires: What we know about the victims

David Ricks of Eli Lilly: best biopharma CEO of 2023

hotspot

hotspot

leisure time

focus